

Corrigendum: Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios as Predictors of Outcomes in Patients With Unresectable Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization Plus Sorafenib

OPEN ACCESS

Approved by:

Frontiers Editorial Office, Frontiers Media SA, Switzerland

*Correspondence:

Qiang Li rmligiang@nbu.edu.cn

[†]These authors have contributed equally to this work and share first authorship

[‡]These authors have contributed

Specialty section:

This article was submitted to Molecular Diagnostics and Therapeutics, a section of the journal Frontiers in Molecular Biosciences

> Received: 20 June 2021 Accepted: 30 July 2021 Published: 30 August 2021

Citation:

Zhang L, Yan Z-P, Hou Z-H, Huang P, Yang M-J, Zhang S, Zhang S, Zhang S-H, Zhu X-L, Ni C-F and Li Q (2021) Corrigendum: Neutrophil-to-Lymphocyte Ratios as Predictors of Outcomes in Patients With Unresectable Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization Plus Sorafenib. Front. Mol. Biosci. 8:727969. doi: 10.3389/fmolb.2021.727969

Lei Zhang^{1†}, Zhi-Ping Yan^{2,3,4†}, Zhong-Heng Hou^{1†}, Peng Huang^{1†}, Min-Jie Yang^{2,3,4}, Shuai Zhang¹, Shen Zhang¹, Shao-Hua Zhang⁵, Xiao-Li Zhu^{1‡}, Cai-Fang Ni^{1‡} and Qiang Li^{6*‡}

¹Department of Interventional Radiology, The First Affiliated Hospital of Soochow University, Suzhou, China, ²Department of Interventional Radiology, Zhongshan Hospital, Fudan University, Shanghai, China, ³Shanghai Institution of Medical Imaging, Shanghai, China, ⁴National Clinical Research Center for Interventional Medicine, Shanghai, China, ⁵Institute of Urology, The Affiliated Luohu Hospital of Shenzhen University, Shenzhen, China, ⁶Department of Radiology, The Affiliated People's Hospital of Ningbo University, Ningbo, China

Keywords: TACE, sorafenib, HCC, platelet count, neutrophils, lymphocytes

1

A Corrigendum on

Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios as Predictors of Outcomes in Patients With Unresectable Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization Plus Sorafenib

by Zhang, L., Yan, Z.-P., Hou, Z.-H., Huang, P., Yang, M.-J., Zhang, S., Zhang, S., Zhang, S.-H., Zhu, X.-L., Ni, C.-F., and, Li, Q (2021). Front. Mol. Biosci. 8:624366. doi: 10.3389/fmolb.2021.624366

In the published article, there was an error regarding the affiliations for Lei Zhang and Cai-Fang Ni. One of the affiliations was added in error. This has now been removed.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher's Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2021 Zhang, Yan, Hou, Huang, Yang, Zhang, Zhang, Zhang, Zhu, Ni and Li. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.